Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

BACKGROUND: Cangrelor is an intravenous P2Y(12) inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y(12) inhibitor. METHODS: A total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPI...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation
Hlavní autoři: Cavender, Matthew A., Bhatt, Deepak L., Stone, Gregg W., White, Harvey D., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Leonardi, Sergio, Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., Harrington, Robert A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2016
Témata:
Original Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006794/
https://ncbi.nlm.nih.gov/pubmed/27482008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.115.020829
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky